Correspondence to editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures” Mengyi Zhang, Yee Hui Yeo, Jian Zu, Jonel Trebicka, Fanpu Ji Clinical and Molecular Hepatology.2026; 32(3): e346. CrossRef
Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2025;31(Suppl):S1-S31. Published online February 19, 2025
Metabolic dysfunction-associated steatotic liver disease and adverse pregnancy outcomes: a nationwide cohort study Young Mi Jung, Taesu Kim, Min-Jeong Oh, Dong Hyeon Lee, Geum Joon Cho, Won Kim Hepatology International.2026; 20(1): 69. CrossRef
Unmasking Kidney Risk in Steatotic Liver Disease: A Call for Metabolic Precision Chan-Young Jung Gut and Liver.2026; 20(1): 1. CrossRef
Prognostic value of non-invasive fibrosis assessment scores in predicting mortality among individuals with metabolic dysfunction-associated steatotic liver disease Lingjie Wu, Shunling Cai, Zhongbin Lin, Ruilie Chen, Yuanfeng Zhang, Xiaobing Gong BMC Public Health.2026;[Epub] CrossRef
Optimal screening criteria for metabolic dysfunction-associated steatotic liver disease with fibrosis Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Annals of Hepatology.2026; 31(2): 102199. CrossRef
Managing Metabolic Dysfunction–Associated Steatotic Liver Disease: Protocol for a Scoping Review of Patient Perceptions, Barriers, and Facilitators Sikyeong Park, Yu Shin Park, Dahye Hong, Bada Kang JMIR Research Protocols.2026; 15: e81404. CrossRef
Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm Chan‐Young Jung, Hye Won Lee, Jung Il Lee, Han Ah Lee, Seung Up Kim Diabetes, Obesity and Metabolism.2026; 28(6): 5240. CrossRef
Rethinking first-line screening in MASLD beyond the limitations of Fibrosis-4 index: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease” Han Ah Lee, Young Youn Cho, Hyung Joon Kim Clinical and Molecular Hepatology.2026; 32(2): 921. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease: On track to become the dominant etiology of hepatocellular carcinoma: Reply to correspondence on “Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta- Jian Xu, Wei Zhang, Guo Wu, Jingdong Li Clinical and Molecular Hepatology.2026; 32(2): e257. CrossRef
Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia Soo Lim, Hui Zhou, Wataru Ogawa Journal of Obesity & Metabolic Syndrome.2026; 35(2): 130. CrossRef
Evolving B-mode ultrasound-based techniques for assessing metabolic dysfunction-associated steatotic liver disease: Now and beyond Walaa Abdelhamed, Mohamed Elbadry, Mohamed El-Kassas Liver Research.2026; 10(2): 109. CrossRef
Baduanjin for Non-Alcoholic Fatty Liver Disease: A Systematic Review Hyo-Ju Woo, Jung-Gyung Lee, Bong-Jin Shin, Jae-Jin Han, Sun-Young Park, Eui-Hyoung Hwang Journal of Korean Medicine Rehabilitation.2026; 36(2): 85. CrossRef
Surgically confirmed severe endometriosis is associated with lower risk of steatotic liver disease: Evidence of estrogen‐linked hepatic–reproductive crosstalk Jung Hyun Park, Keungmo Yang, Hyun Yang, Si Hyun Bae, Mee‐Ran Kim, Jaejun Lee International Journal of Gynecology & Obstetrics.2026;[Epub] CrossRef
Non-Invasive Tests in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Diagnosis to Treatment Monitoring Han Ah Lee, Young Youn Cho, Hyung Joon Kim Clinical Ultrasound.2026; 11(1): 1. CrossRef
An Arterial‐Enhancing Liver Nodule With Washout in a Patient With Metabolic and Alcohol‐Associated Liver Disease Soon Kyu Lee, Sun Young Jun, Young Chul Yoon Journal of Gastroenterology and Hepatology.2026; 41(7): 1991. CrossRef
Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol-related liver disease in human immunodeficiency virus Dinuka Bandara, Krishan Joshi, Carol Singh, Aalam Sohal, Mohanad Al-Qaisi, Nilofar Najafian World Journal of Virology.2026;[Epub] CrossRef
CT attenuation–based hepatic steatosis assessment using 3D organ segmentation: Impact of tube voltage and need for cutoff adjustment Jeongin Yoo, Ijin Joo, Sun Kyung Jeon, Junghoan Park, Jeong Min Lee European Journal of Radiology.2026; 203: 113021. CrossRef
Alcohol consumption and dementia risk in steatotic liver disease: a nationwide cohort study Ji Won Han, Seunghee Na, Kyungdo Han, Kyu Na Lee, Do Young Kim, Sang Hoon Ahn, Mi Na Kim Hepatology International.2026;[Epub] CrossRef
Pharmacological treatment of metabolic dysfunction–associated steatotic liver disease: a narrative review Jeong-Hwan Lee, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Journal of the Korean Medical Association.2026; 69(6): 492. CrossRef
Uric Acid-to-HDL Cholesterol Ratio is Associated with Hepatic Steatosis but Not Fibrosis in Nonobese Adults: A NHANES 2017–2020 Study Linwan Li, Xiang’an Zhao Metabolic Syndrome and Related Disorders.2026; 24(8): 383. CrossRef
Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis Xin-Yue Sun, Hua-Ling Jiang, Yu-Tong Ma, Tian-Qi Xiong, Xie-Yuan Leng, Yi-Fan Zhao, Xian-Feng Shen, Chao Zhang, Yi-Jun Tang Journal of Translational Medicine.2026;[Epub] CrossRef
Steatotic liver disease subtypes and risk of hospitalization for sepsis: a nationwide cohort study Hye Seong, Se Yun Kim, Eun Hwa Lee, Dayeong Kim, Kyung Do Han, Sang Hoon Han Annals of Medicine.2026;[Epub] CrossRef
Emerging Indices Outperform Traditional Fibrosis Scores in Young Metabolic Dysfunction‐Associated Steatotic Liver Disease Across Divergent Screening Goals Ahlim Lee, Chang In Han, Keungmo Yang, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Jaejun Lee Journal of Gastroenterology and Hepatology.2026; 41(9): 2925. CrossRef
Steatotic Liver Disease Predicts Lower Likelihood of LDLR Gene Mutations in Young Korean Patients with Suspected Familial Hypercholesterolemia Chang In Han, Sung Hyun Cho, Keungmo Yang, Hyun Yang, Si Hyun Bae, Jaejun Lee Journal of Obesity & Metabolic Syndrome.2026; 35(3): 370. CrossRef
Correspondence to editorial 1 on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis” Moon Haeng Hur, Hyunjae Shin, Yoon Jun Kim Clinical and Molecular Hepatology.2026; 32(3): e378. CrossRef
Hepatic fibro-inflammation measured by magnetic resonance imaging iron-corrected T1 predicts extrahepatic cancer risk: a UK Biobank study Hye Yeon Chon, Seok-Jae Heo, SungA Bae, Tae Seop Lim, Ja Kyung Kim Clinical and Molecular Hepatology.2026; 32(3): 1349. CrossRef
The risk of cardiovascular events in metabolic dysfunction–associated steatotic liver disease according to fibrosis stage and diabetes status: A cohort study Jaehong Jeong, Jung Pyo Hong, Dong Yun Kim, Jae Seung Lee, Mi Na Kim, Jeong Eun Song, Hyun Chin Cho, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Hye Won Lee, Seung Up Kim Hepatology Communications.2026;[Epub] CrossRef
Correspondence to editorial 2 on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis” Hyunjae Shin, Moon Haeng Hur, Yoon Jun Kim Clinical and Molecular Hepatology.2026; 32(3): e381. CrossRef
Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy Young Eun Chon, Kyung‐Do Han, Ju Dong Yang, Ju‐Yeong Park, Hyun‐Seok Kim, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2026; 41(9): 2913. CrossRef
Liver transplantation in patients with metabolic dysfunction-associated steatotic liver disease: a narrative review Suk Kyun Hong Journal of the Korean Medical Association.2026; 69(8): 631. CrossRef
Association Between Food Insecurity and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study in South Korea Seong-Uk Baek, Jin-Ha Yoon Nutrients.2026; 18(17): 2806. CrossRef
Guest editorial introduction to the special issue on “A Multidisciplinary Approach to Metabolic Dysfunction-Associated Steatotic Liver Disease: from Primary Care to Liver Transplantation” Won Kim Journal of the Korean Medical Association.2026; 69(8): 595. CrossRef
Bariatric surgery as a therapeutic strategy for metabolic dysfunction-associated steatotic liver disease in patients with obesity: a narrative review Yuri Cho Journal of the Korean Medical Association.2026; 69(8): 612. CrossRef
Primary care evaluation and fibrosis risk assessment of metabolic dysfunction-associated steatotic liver disease: a narrative review Hye Won Lee Journal of the Korean Medical Association.2026; 69(8): 598. CrossRef
Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: a narrative review of pathophysiology, diagnostic value, and therapeutic approaches Jung Woo Eun, Jae Youn Cheong, Soon Sun Kim Journal of the Korean Medical Association.2026; 69(8): 619. CrossRef
Dietary management of metabolic dysfunction-associated steatotic liver disease in the era of pharmacotherapy: a narrative review Joo Hyun Oh Journal of the Korean Medical Association.2026; 69(8): 603. CrossRef
Differential Infiltration of T-Cell Populations in Tumor and Liver Tissues Predicts Recurrence-Free Survival in Surgically Resected Hepatocellular Carcinoma Eun Ji Jang, Ho Joong Choi, Young Kyoung You, Deok Hwa Seo, Mi Hyun Kwon, Keungmo Yang, Jaejun Lee, Jeong Won Jang, Seung Kew Yoon, Ji Won Han, Pil Soo Sung Cancers.2025; 17(9): 1548. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease, Recent Revision of Terminology and Its Implications Hyo Young Lee, Eileen L. Yoon The Korean Journal of Gastroenterology.2025; 85(2): 126. CrossRef
Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li Biomedicine & Pharmacotherapy.2025; 188: 118191. CrossRef
A Case Report of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Improved Cardiometabolic Risk Factors Following Treatment with Saenggangunbi-tang Eun Kyung Lee, Min Jeong Park, Youngchul Kim, Jang-Hoon Lee The Journal of Internal Korean Medicine.2025; 46(2): 303. CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi Nutrients.2025; 17(13): 2211. CrossRef
Associations between steatotic liver disease subtypes and incident atrial fibrillation in young adults: a nationwide cohort study Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho Cardiovascular Diabetology.2025;[Epub] CrossRef
Second-line antidiabetic drugs: friend or foe of the liver Jiwon Yang, Gunho Kim, Ju Hyun Shim, Jihyun An Journal of Liver Cancer.2025; 25(2): 187. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
2025 Clinical Practice Guidelines for Diabetes: Management of Metabolic Dysfunction-Associated Steatotic Liver Disease Jaehyun Bae The Journal of Korean Diabetes.2025; 26(3): 172. CrossRef
Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang Hepatology Communications.2025;[Epub] CrossRef
Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease Ralf Weiskirchen, Amedeo Lonardo International Journal of Molecular Sciences.2025; 26(19): 9594. CrossRef
Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li European Journal of Medical Research.2025;[Epub] CrossRef
Risk of Esophageal and Gastric Cancer by Histologic Subtype in Steatotic Liver Disease: A UK Biobank Study Donghoon Kang, Ji Won Han, Kenneth R. Muir, Artitaya Lophatananon, Jongin Lee Cancers.2025; 17(21): 3416. CrossRef
Implication of the Androgen Receptor in Muscle–Liver Crosstalk: An Overlooked Mechanistic Link in Lean-MASLD Eleni Myrto Trifylli, Christiana Charalambous, Nikolaos Spiliotopoulos, Nikolaos Papadopoulos, Anastasia Oikonomou, Spilios Manolakopoulos, Melanie Deutsch Livers.2025; 5(4): 65. CrossRef
Time-updated FIB-4 index predicts coronary artery calcification progression in individuals with metabolic dysfunction–associated steatotic liver disease Yesung Lee, Woncheol Lee Scientific Reports.2025;[Epub] CrossRef
Background/Aims We investigated the outcomes of early-stage hepatocellular carcinoma (HCC) patients who showed a complete response (CR) to initial transarterial chemoembolization (TACE), with a focus on the role of scheduled TACE repetition.
Methods A total of 178 patients with early-stage HCC who were initially treated with TACE and showed a CR based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria on one month follow-up computed tomography (CT) were analyzed. Among them, 90 patients underwent scheduled repetition of TACE in the absence of viable tumor on CT.
Results During a median follow-up period of 4.6 years (range: 0.4-8.8 years), mortality was observed in 71 patients (39.9%). The overall recurrence-free and local recurrence-free survival rates at 1 year were 44.4% and 56.2%. In the multivariable model, scheduled repetition of TACE was an independent factor associated with survival (hazard ratio [95% confidence interval]: 0.56 [0.34-0.93], P=0.025). When stratified using Barcelona clinic liver cancer (BCLC) stage, scheduled repetition of TACE was associated with a favorable survival rate in BCLC stage A patients, but not in BCLC 0 patients.
Conclusions Scheduled repetition of TACE was associated with better survival for early-stage HCC patients showing a CR after initial TACE, especially in BCLC stage A patients.
Citations
Citations to this article as recorded by
Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure Jiahao Li, Yingnan Liu, Ruipeng Zheng, Chao Qu, Jiarui Li Life Sciences.2024; 342: 122540. CrossRef
Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma Shamar Young, Tina Sanghvi, Sandeep Sharma, Cameron Richardson, Nathan Rubin, Masters Richards, Donna D'Souza, Siobhan Flanagan, Jafar Golzarian Diagnostic and Interventional Imaging.2022; 103(3): 143. CrossRef
Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients Woo Jin Jung, Sangmi Jang, Won Joon Choi, Jaewon Park, Gwang Hyeon Choi, Eun Sun Jang, Sook-Hyang Jeong, Won Seok Choi, Jae Hwan Lee, Chang Jin Yoon, Jin-Wook Kim Scientific Reports.2022;[Epub] CrossRef
Research Progress on the Predictive Value of Early Curative Effect after TACE for Hepatocellular Carcinoma 志祥 刘 Advances in Clinical Medicine.2022; 12(11): 10342. CrossRef
Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma Jae Seung Lee, Young Eun Chon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Wonseok Kang, Moon Seok Choi, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Hwi Young Kim, Tae Hun Kim, Kwon Yoo, Yonsei Medical Journal.2021; 62(1): 12. CrossRef
Association between Time to Local Tumor Control and Treatment Outcomes Following Repeated Loco-Regional Treatment Session in Patients with Hepatocellular Carcinoma: A Retrospective, Single-Center Study Krzysztof Bartnik, Wacław Hołówko, Olgierd Rowiński Life.2021; 11(10): 1062. CrossRef
Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Cancers.2021; 14(1): 67. CrossRef
Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection Mi Young Jeon, Hye Soo Kim, Tae Seop Lim, Dai Hoon Han, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Gi Hong Choi, Jin Sub Choi, Kwang-Hyub Han, Seung Up Kim, Gianfranco D. Alpini PLOS ONE.2019; 14(4): e0214613. CrossRef
Long-Term Efficacy and Safety of Partial Splenic Embolization in Hepatocellular Carcinoma Patients with Thrombocytopenia Who Underwent Transarterial Chemoembolization Nam Hee Kim, Hong Joo Kim, Yong Kyun Cho, Hyun Pyo Hong, Byung Ik Kim Journal of Korean Medical Science.2019;[Epub] CrossRef
A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study Shintaro Shiba, Kei Shibuya, Hiroyuki Katoh, Takuya Kaminuma, Masaya Miyazaki, Satoru Kakizaki, Ken Shirabe, Tatsuya Ohno, Takashi Nakano Radiation Oncology.2019;[Epub] CrossRef
Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma Yaojun Zhang, Mengping Zhang, Minshan Chen, Jie Mei, Li Xu, Rongping Guo, Xiaojun Lin, Jiaping Li, Zhenwei Peng JAMA Network Open.2018; 1(6): e183213. CrossRef
First
Prev
